CRVS · XBRL financial data

Corvus Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2021Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	31,830	29,115	24,468	16,526	19,385	33,719
General and administrative	11,930	9,515	8,097	6,881	8,163	9,252
Total operating expenses	43,760	38,630	32,565	23,407	27,548	42,971
Operating income (loss)	(43,760)	(38,630)	(32,565)	(23,407)	(27,548)	(42,971)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(5,995)	(43,241)	(41,307)	(27,029)	(62,293)	(15,283)
Earnings per share, basic USD per share	(0.20)	(1.03)	(0.89)	(0.56)	(1.02)	(0.19)
Earnings per share, diluted USD per share	(0.20)	(1.03)	(0.89)	(0.56)	(1.02)	(0.53)
Weighted average shares, basic thousands of shares	29,479	41,854	46,554	48,025	60,985	78,965
Weighted average shares, diluted thousands of shares	29,479	41,854	46,554	48,025	60,985	79,743

Fiscal years (CRVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2021Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,455	63,458	13,159	12,620	8,740	4,576
Marketable securities	—	—	—	—	43,224	52,174
Accounts receivable	—	—	588	26	75	37
Prepaid and other current assets	1,077	1,354	773	781	2,368	1,427
Total current assets	45,336	71,312	43,664	27,956	54,407	58,214
Property and equipment, net	906	451	353	236	151	220
Right-of-use asset	1,648	3,190	2,217	1,149	1,177	839
Total assets	85,529	109,455	68,240	45,553	68,907	71,119
Accounts payable	3,467	1,565	1,976	1,525	2,582	2,491
Accrued liabilities	—	—	—	3,970	3,725	6,486
Total current liabilities	12,149	9,692	10,752	6,869	35,402	9,380
Lease liability, non-current	1,232	2,601	1,373	—	937	534
Total liabilities	13,381	12,293	12,125	6,869	36,339	9,914
Accumulated deficit	(223,140)	(266,381)	(307,688)	(334,717)	(397,010)	(412,293)
Total stockholders' equity	72,148	97,162	56,115	38,684	32,568	61,205
Total liabilities and equity	85,529	109,455	68,240	45,553	68,907	71,119
Common shares outstanding (cover page) thousands of shares	38,310	46,554	46,569	49,039	68,136	83,992

Fiscal years (CRVS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2021Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(5,995)	(43,241)	(41,307)	(27,029)	(62,293)	(15,283)
Stock-based compensation	5,747	4,232	2,692	2,147	3,003	5,330
Depreciation and amortization	632	460	367	151	85	105
Net cash from operating activities	(34,778)	(36,715)	(27,023)	(23,935)	(25,424)	(32,797)
Purchases of property and equipment	76	5	269	34	—	174
Net cash from investing activities	44,769	21,560	(23,276)	15,541	(27,484)	(7,796)
Proceeds from issuing common stock	—	31,989	—	—	16,405	—
Net cash from financing activities	1,310	62,158	0	7,855	49,028	36,429
Net change in cash	11,301	47,003	(50,299)	(539)	(3,880)	(4,164)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.